Early Promising Signs in Verubecestat Human Drug Trial (NHS Choices / Science Translational Medicine / Translational Neurodegeneration)


Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults.

As usual NHS ChoicesBehind the Headlines offers due perspective, without over-dampening readers’ enthusiasm.

Full Text Link


Promising Alzheimer’s drug ‘clears early hurdle’. London: NHS Choices; Behind the Headlines, November 3rd 2016.

This relates to:

Full Text Link


Kennedy, ME. Stamford, AW. [and] Chen, X. [et al] (2016). The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Science Translational Medicine. November 2nd 2016. [Epub ahead of print].

Possibly of interest:

Full Text Link


Yan, R. (2016). Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs. Translational Neurodegeneration. July 2016. 14(5): 13.


About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in Animal Studies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Choices, Pharmacological Treatments, Quick Insights, Universal Interest and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s